Entering text into the input field will update the search result below

Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q1 2020 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2020 Earnings Conference Call May 6, 2020 5:00 PM ET

Company Participants

Danielle Keatley - Senior Director of IR

Emil Kakkis - CEO and President

Shalini Sharp - CFO

Camille Bedrosian - Chief Medical Officer

Erik Harris - Chief Commercial Officer

Conference Call Participants

Yaron Werber - Cowen

Maury Raycroft - Jefferies

Laura Chico - Wedbush

Samantha Semenkow - Citi

Jon Wolleben - JMP Securities


Ladies and gentlemen, thank you for standing by. And welcome to the Ultragenyx First Quarter 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Please be advised that today's conference may be recorded. [Operator Instructions]

I would now like to hand the call over to your speaker today, Ms. Danielle Keatley. Please go ahead.

Danielle Keatley

Good afternoon. And welcome to the Ultragenyx Pharmaceutical financial results and corporate update conference call for the first quarter of 2020. We've issued a press release detailing our financial results, which you can find on our website at ultragenyx.com.

I'm Danielle Keatley, Senior Director of Investor Relations. Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Shalini Sharp, Chief Financial Officer; Camille Bedrosian, Chief Medical Officer; and Erik Harris, Chief Commercial Officer.

I would like to remind investors this call will include forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to the types of statements identified as forward-looking in our 2019 annual report on Form 10-K that was filed on February 14, 2020, our quarterly report on Form 10-Q that will be filed soon, and our subsequent periodic reports filed with the SEC, which will all be available on our website in the Investors section.

These forward-looking statements

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.